nach oben

Clinical Reviews in Allergy & Immunology

Erschienen in:

19.01.2022 | COVID-19 Zur Zeit gratis

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

verfasst von: Jin-jin Zhang, Xiang Dong, Guang-hui Liu, Ya-dong Gao

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global health crisis. Currently, a number of risk factors have been identified to have a potential impact on increasing the morbidity of COVID-19 in adults, including old age, male sex, pre-existing comorbidities, and racial/ethnic disparities. In addition to these factors, changes in laboratory indices and pro-inflammatory cytokines, as well as possible complications, could indicate the progression of COVID-19 into a severe and critical stage. Children predominantly suffer from mild illnesses due to COVID-19. Similar to adults, the main risk factors in pediatric patients include age and pre-existing comorbidities. In contrast, supplementation with a healthy diet and sufficient nutrition, COVID-19 vaccination, and atopic conditions may act as protective factors against the infection of SARS-CoV-2. COVID-19 vaccination not only protects vulnerable individuals from SARS-CoV-2 infection, more importantly, it may also reduce the development of severe disease and death due to COVID-19. Currently used therapies for COVID-19 are off-label and empiric, and their impacts on the severity and mortality of COVID-19 are still unclear. The interaction between asthma and COVID-19 may be bidirectional and needs to be clarified in more studies. In this review, we highlight the clinical evidence supporting the rationale for the risk and protective factors for the morbidity, severity, and mortality of COVID-19.

World Health Organization (WHO) (2021) Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed 27th December 2021

Li G, Fan Y, Lai Y et al (2020) Coronavirus infections and immune responses. J Med Virol 92:424–432. https://doi.org/10.1002/jmv.25685CrossRef

Fauci AS, Lane HC, Redfield RR (2020) Covid-19—navigating the uncharted. N Engl J Med 382:1268–1269. https://doi.org/10.1056/NEJMe2002387CrossRef

Dong Y, Mo X, Hu Y et al (2020) Epidemiology of COVID-19 among children in China. Pediatrics 145:e20200702

Graff K, Smith C, Silveira L et al (2021) Risk factors for severe COVID-19 in children. Pediatr Infect Dis J 40:e137–e145CrossRef

Tsankov BK, Allaire JM, Irvine MA et al (2021) Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 103:246–256CrossRef

Saatci D, Ranger TA, Garriga C et al (2021) Association between race and COVID-19 outcomes among 2.6 million children in England. JAMA Pediatr 175:928–938CrossRef

Gao YD, Ding M, Dong X et al (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428–455. https://doi.org/10.1111/all.14657CrossRef

Mulchandani R, Lyngdoh T, Kakkar AK (2021) Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest 51:e13429. https://doi.org/10.1111/eci.13429CrossRef

10.

Gao Y, Li T, Han M et al (2020) Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92:791–796. https://doi.org/10.1002/jmv.25770CrossRef

11.

Wolff D, Nee S, Hickey NS, Marschollek M (2021) Risk factors for Covid-19 severity and fatality: a structured literature review. Infection 49:15–28. https://doi.org/10.1007/s15010-020-01509-1CrossRef

12.

Shakoor H, Feehan J, Al Dhaheri AS et al (2021) Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: could they help against COVID-19? Maturitas 143:1–9. https://doi.org/10.1016/j.maturitas.2020.08.003CrossRef

13.

Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT (2021) SARS-CoV-2 vaccines in advanced clinical trials: where do we stand? Adv Drug Deliv Rev 172:314–338. https://doi.org/10.1016/j.addr.2021.01.014CrossRef

14.

Keswani A, Dhana K, Rosenthal JA, Moore D, Mahdavinia M (2020) Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019. Ann Allergy Asthma Immunol 125:479–481. https://doi.org/10.1016/j.anai.2020.07.012CrossRef

15.

Flook M, Jackson C, Vasileiou E et al (2021) Informing the public health response to COVID-19: a systematic review of risk factors for disease, severity, and mortality. BMC Infect Dis 21:342. https://doi.org/10.1186/s12879-021-05992-1CrossRef

16.

Pijls BG, Jolani S, Atherley A et al (2021) Demographic risk factors for COVID-19 infection, severity, ICU admission and death: a meta-analysis of 59 studies. BMJ, (Open) 11:e044640. https://doi.org/10.1136/bmjopen-2020-044640

17.

Davies NG, Klepac P, Liu Y et al (2020) Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 26:1205–1211. https://doi.org/10.1038/s41591-020-0962-9CrossRef

18.

Ayoub HH, Chemaitelly H, Mumtaz GR et al (2020) Characterizing key attributes of COVID-19 transmission dynamics in China’s original outbreak: model-based estimations. Glob Epidemiol 2:100042. https://doi.org/10.1016/j.gloepi.2020.100042CrossRef

19.

Shaw AC, Joshi S, Greenwood H, Panda A, Lord JM (2010) Aging of the innate immune system. Curr Opin Immunol 22:507–513. https://doi.org/10.1016/j.coi.2010.05.003CrossRef

20.

Papadopoulos V, Li L, Samplaski M (2021) Why does COVID-19 kill more elderly men than women? Is there a role for testosterone? Andrology 9:65–72. https://doi.org/10.1111/andr.12868CrossRef

21.

Lisco G, Tullio AD, Stragapede A et al (2021) COVID-19 and the endocrine system: a comprehensive review on the theme. J Clin Med 10:2920. https://doi.org/10.3390/jcm10132920CrossRef

22.

Abedi V, Olulana O, Avula V et al (2021) Racial, economic, and health inequality and COVID-19 infection in the United States. J Racial Ethn Health Disparities 8:732–742. https://doi.org/10.1007/s40615-020-00833-4CrossRef

23.

Bouillon R, Marcocci C, Carmeliet G et al (2019) Skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40:1109–1151. https://doi.org/10.1210/er.2018-00126CrossRef

24.

Grant WB, Lahore H, McDonnell SL et al (2020) Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12.https://doi.org/10.3390/nu12040988

25.

Khan HM, Parikh N, Megala SM, Predeteanu GS (2020) Unusual early recovery of a critical COVID-19 patient after administration of intravenous vitamin C. Am J Case Rep 21:e925521. https://doi.org/10.12659/AJCR.925521

26.

Boechat JL, Wandalsen GF, Kuschnir FC, Delgado L (2021) COVID-19 and pediatric asthma: clinical and management challenges. Int J Environ Res Public Health 18. https://doi.org/10.3390/ijerph18031093

27.

Jackson DJ, Busse WW, Bacharier LB et al (2020) Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol 146:203-206.e3CrossRef

28.

Taquechel K, Diwadkar AR, Sayed S et al (2020) Pediatric asthma health care utilization, viral testing, and air pollution changes during the COVID-19 pandemic. J Allergy Clin Immunol Pract 8:3378-3387.e11. https://doi.org/10.1016/j.jaip.2020.07.057CrossRef

29.

Pradhan A, Olsson PE (2020) Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ 11:53. https://doi.org/10.1186/s13293-020-00330-7CrossRef

30.

Zheng Z, Peng F, Xu B et al (2020) Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Infect 81:e16–e25. https://doi.org/10.1016/j.jinf.2020.04.021CrossRef

31.

Zachariah P, Johnson CL, Halabi KC et al (2020) Epidemiology, clinical features, and disease severity in patients with coronavirus disease 2019 (COVID-19) in a Children’s Hospital in New York City. New York JAMA Pediatr 174:e202430. https://doi.org/10.1001/jamapediatrics.2020.2430CrossRef

32.

Cummings MJ, Baldwin MR, Abrams D et al (2020) Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 395:1763–1770. https://doi.org/10.1016/S0140-6736(20)31189-2CrossRef

33.

Terpos E, Ntanasis-Stathopoulos I, Elalamy I et al (2020) Hematological findings and complications of COVID-19. Am J Hematol 95:834–847. https://doi.org/10.1002/ajh.25829CrossRef

34.

Cao M, Zhang D, Wang Y et al (2020) Clinical features of patients infected with the 2019 novel coronavirus (COVID-19) in Shanghai, China. medRxiv 20030395. https://doi.org/10.1101/2020.03.04.20030395

35.

Fu L, Fei J, Xu S et al (2020) Acute liver injury and its association with death risk of patients with COVID-19: a hospital-based prospective case-cohort study medRxiv 20050997. https://doi.org/10.1101/2020.04.02.20050997

36.

Chen Y, Wang Y, Fleming J et al (2020) Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity medRxiv 20033795. https://doi.org/10.1101/2020.03.10.20033795

37.

Li LQ, Huang T, Wang YQ et al (2020) COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 92:577–583. https://doi.org/10.1002/jmv.25757CrossRef

38.

Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720. https://doi.org/10.1056/NEJMoa2002032CrossRef

39.

Liu R, Han H, Liu F et al (2020) Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020. Clin Chim Acta 505:172–175. https://doi.org/10.1016/j.cca.2020.03.009CrossRef

40.

Singh MK, Mobeen A, Chandra A, Joshi S, Ramachandran S (2021) A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection? Comput Biol Med 130:104219. https://doi.org/10.1016/j.compbiomed.2021.104219CrossRef

41.

Guan WJ, Liang WH, Zhao Y et al (2020) Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 55. https://doi.org/10.1183/13993003.00547-2020

42.

Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:507–513. https://doi.org/10.1016/S0140-6736(20)30211-7CrossRef

43.

Böhm M, Frey N, Giannitsis E, Sliwa K, Zeiher AM (2020) Coronavirus disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation. Clin Res Cardiol 109:1446–1459. https://doi.org/10.1007/s00392-020-01656-3CrossRef

44.

Zeng JH, Liu YX, Yuan J et al (2020) First case of COVID-19 complicated with fulminant myocarditis: a case report and insights. Infection 48:773–777. https://doi.org/10.1007/s15010-020-01424-5CrossRef

45.

Varga Z, Flammer AJ, Steiger P et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395:1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRef

46.

Russell B, Moss CL, Palmer K et al (2021) COVID-19 risk factors for cancer patients: a first report with comparator data from COVID-19 negative cancer patients. Cancers (Basel) 13. https://doi.org/10.3390/cancers13102479

47.

Kam KQ, Yung CF, Cui L (2020) A well infant with coronavirus disease 2019 (COVID-19) with high viral load. Clin Infect Dis 71:847–849. https://doi.org/10.1093/cid/ciaa201CrossRef

48.

Tsabouri S, Makis A, Kosmeri C, Siomou E (2021) Risk factors for severity in children with coronavirus disease 2019: a comprehensive literature review. Pediatr Clin North Am 68:321–338. https://doi.org/10.1016/j.pcl.2020.07.014CrossRef

49.

Huang A, Bange E, Han N et al (2021) CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Res Sq. https://doi.org/10.21203/rs.3.rs-162289/v1

50.

Mackey K, Ayers CK, Kondo KK et al (2021) Racial and ethnic disparities in COVID-19-related infections, hospitalizations, and deaths: a systematic review. Ann Intern Med 174:362–373. https://doi.org/10.7326/M20-6306CrossRef

51.

Rodriguez F, Solomon N, de Lemos JA et al (2021) Racial and ethnic differences in presentation and outcomes for patients hospitalized with COVID-19: findings from the American Heart Association’s COVID-19 Cardiovascular Disease Registry. Circulation 143:2332–2342. https://doi.org/10.1161/CIRCULATIONAHA.120.052278CrossRef

52.

Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C (2020) COVID-19: the case for health-care worker screening to prevent hospital transmission. Lancet 395:1418–1420. https://doi.org/10.1016/S0140-6736(20)30917-XCrossRef

53.

CDC COVID-19 Response Team (2020) Characteristics of health care personnel with COVID-19—United States, 12 Feb-9 Apr 2020. MMWR Morb Mortal Wkly Rep 69:477–481. https://doi.org/10.15585/mmwr.mm6915e6

54.

Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323:1239–1242. https://doi.org/10.1001/jama.2020.2648CrossRef

55.

Nguyen LH, Drew DA, Graham MS et al (2020) Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health 5:e475–e483. https://doi.org/10.1016/S2468-2667(20)30164-XCrossRef

56.

Misra-Hebert AD, Jehi L, Ji X et al (2020) Impact of the COVID-19 pandemic on healthcare workers’ risk of infection and outcomes in a large, integrated health system. J Gen Intern Med 35:3293–3301. https://doi.org/10.1007/s11606-020-06171-9CrossRef

57.

Gholami M, Fawad I, Shadan S et al (2021) COVID-19 and healthcare workers: a systematic review and meta-analysis. Int J Infect Dis 104:335–346. https://doi.org/10.1016/j.ijid.2021.01.013CrossRef

58.

Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D (2021) Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect 108:120–134CrossRef

59.

Campi I, Gennari L, Merlotti D et al (2021) Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect Dis 21:566. https://doi.org/10.1186/s12879-021-06281-7CrossRef

60.

Panagiotou G, Tee SA, Ihsan Y et al (2020) Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalized with COVID-19 are associated with greater disease severity. Clin Endocrinol (Oxf) 93:508–511. https://doi.org/10.1111/cen.14276CrossRef

61.

Hernández JL, Nan D, Fernandez-Ayala M et al (2021) Vitamin D status in hospitalized patients with SARS-CoV-2 infection. J Clin Endocrinol Metab 106:e1343–e1353:e1343–1343. https://doi.org/10.1210/clinem/dgaa733

62.

Hosseini Z, Whiting SJ, Vatanparast H (2019) Type 2 diabetes prevalence among Canadian adults—dietary habits and sociodemographic risk factors. Appl Physiol Nutr Metab 44:1099–1104. https://doi.org/10.1139/apnm-2018-0567CrossRef

63.

Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ (2021) What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 21:e26–e35. https://doi.org/10.1016/S1473-3099(20)30773-8CrossRef

64.

World Health Organization (WHO) (2021) COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 27^th Dec 2021

65.

Zhang Y, Zeng G, Pan H et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21:181–192. https://doi.org/10.1016/S1473-3099(20)30843-4CrossRef

66.

Wu Z, Hu Y, Xu M et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 21:803–812. https://doi.org/10.1016/S1473-3099(20)30987-7CrossRef

67.

De Faria E, Guedes AR, Oliveira MS et al (2021) Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW)—preliminary report medRxiv 21255308. https://doi.org/10.1101/2021.04.12.21255308

68.

Vogel AB, Kanevsky I, Che Y et al (2020) A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates. bioRxiv 280818. https://doi.org/10.1101/2020.09.08.280818

69.

Pawlowski C, Lenehan P, Puranik A et al (2021) FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2:979-992.e8. https://doi.org/10.1101/2021.02.15.21251623CrossRef

70.

Thompson MG, Burgess JL, Naleway AL et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight US locations. MMWR Morb Mortal Wkly Rep 70:495–500. https://doi.org/10.15585/mmwr.mm7013e3

71.

Blain H, Tuaillon E, Gamon L et al (2021) Spike antibody levels of nursing home residents with or without prior COVID-19 3 weeks after a single BNT162b2 vaccine dose. JAMA. https://doi.org/10.1001/jama.2021.6042CrossRef

72.

Scala E, Abeni D, Tedeschi A et al (2021) Atopic status protects from severe complications of COVID-19. Allergy 76:899–902. https://doi.org/10.1111/all.14551CrossRef

73.

Timberlake DT, Narayanan D, Ogbogu PU et al (2021) Severity of COVID-19 in hospitalized patients with and without atopic disease. World Allergy Organ J 14:100508. https://doi.org/10.1016/j.waojou.2021.100508CrossRef

74.

Kimura H, Francisco D, Conway M et al (2020) Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells. J Allergy Clin Immunol 146:80-88.e8CrossRef

75.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRef

76.

Verity R, Okell LC, Dorigatti I et al (2020) Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 20:669–677. https://doi.org/10.1016/S1473-3099(20)30243-7CrossRef

77.

Wu JT, Leung K, Bushman M et al (2020) Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med 26:506–510. https://doi.org/10.1038/s41591-020-0822-7CrossRef

78.

Li J, Huang DQ, Zou B et al (2021) Epidemiology of COVID-19: a systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol 93:1449–1458. https://doi.org/10.1002/jmv.26424CrossRef

79.

Lippi G, Henry BM (2020) Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med 167:105941. https://doi.org/10.1016/j.rmed.2020.105941CrossRef

80.

Leung JM, Yang CX, Tam A et al (2020) ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur Respir J 55. https://doi.org/10.1183/13993003.00688-2020

81.

Cheng DO, Hurst JR (2021) COVID-19 and ‘basal’ exacerbation frequency in COPD. Thorax 76:432–433. https://doi.org/10.1136/thoraxjnl-2020-216637CrossRef

82.

Falagas ME, Mourtzoukou EG, Vardakas KZ (2007) Sex differences in the incidence and severity of respiratory tract infections. Respir Med 101:1845–1863. https://doi.org/10.1016/j.rmed.2007.04.011CrossRef

83.

Gal-Oz ST, Maier B, Yoshida H et al (2019) ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun 10:4295. https://doi.org/10.1038/s41467-019-12348-6CrossRef

84.

Cai Q, Huang D, Ou P et al (2020) COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 75:1742–1752. https://doi.org/10.1111/all.14309CrossRef

85.

Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323:1061–1069. https://doi.org/10.1001/jama.2020.1585CrossRef

86.

Wan S, Xiang Y, Fang W et al (2020) Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 92:797–806. https://doi.org/10.1002/jmv.25783CrossRef

87.

Liang W, Guan W, Chen R et al (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 21:335–337. https://doi.org/10.1016/S1470-2045(20)30096-6CrossRef

88.

Wang L, Li X, Chen H et al (2020) Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China. Am J Nephrol 51:343–348. https://doi.org/10.1159/000507471CrossRef

89.

Bae S, Kim SR, Kim MN, Shim WJ, Park SM (2021) Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. Heart 107:373–380. https://doi.org/10.1136/heartjnl-2020-317901CrossRef

90.

Cai Q, Chen F, Wang T et al (2020) Obesity and COVID-19 severity in a designated hospital in Shenzhen, China. Diabetes Care 43:1392–1398. https://doi.org/10.2337/dc20-0576CrossRef

91.

Goyal P, Choi JJ, Pinheiro LC et al (2020) Clinical characteristics of Covid-19 in New York City. N Engl J Med 382:2372–2374. https://doi.org/10.1056/NEJMc2010419CrossRef

92.

Li B, Yang J, Zhao F et al (2020) Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 109:531–538. https://doi.org/10.1007/s00392-020-01626-9CrossRef

93.

Sarzi-Puttini P, Giorgi V, Sirotti S et al (2020) COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin Exp Rheumatol 38:337–342CrossRef

94.

Qin C, Zhou L, Hu Z et al (2020) Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 71:762–768. https://doi.org/10.1093/cid/ciaa248CrossRef

95.

Ruan Q, Yang K, Wang W, Jiang L, Song J (2020) Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 46:846–848. https://doi.org/10.1007/s00134-020-05991-xCrossRef

96.

Zhang JJ, Dong X, Cao YY et al (2020) Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 75:1730–1741. https://doi.org/10.1111/all.14238CrossRef

97.

Zhang JJ, Cao YY, Tan G et al (2021) Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 76:533–550. https://doi.org/10.1111/all.14496CrossRef

98.

Lin J, Yan H, Chen H et al (2021) COVID-19 and coagulation dysfunction in adults: a systematic review and meta-analysis. J Med Virol 93:934–944. https://doi.org/10.1002/jmv.26346CrossRef

99.

Liu Y, Sun W, Guo Y et al (2020) Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study. Platelets 31:490–496. https://doi.org/10.1080/09537104.2020.1754383CrossRef

100.

Guo W, Li M, Dong Y et al (2020) Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev e3319. https://doi.org/10.1002/dmrr.3319

101.

Chen Q, Zheng Z, Zhang C et al (2020) Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection 48:543–551. https://doi.org/10.1007/s15010-020-01432-5CrossRef

102.

Cron RQ (2020) Coronavirus is the trigger, but the immune response is deadly. Lancet Rheumatol 2:e370–e371. https://doi.org/10.1016/S2665-9913(20)30165-XCrossRef

103.

Magro C, Mulvey JJ, Berlin D et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13. https://doi.org/10.1016/j.trsl.2020.04.007CrossRef

104.

Diao B, Wang C, Tan Y et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 11:827. https://doi.org/10.3389/fimmu.2020.00827CrossRef

105.

Blanco-Melo D, Nilsson-Payant BE, Liu WC et al (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181:1036-1045.e9. https://doi.org/10.1016/j.cell.2020.04.026CrossRef

106.

Jamilloux Y, Henry T, Belot A et al (2020) Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Autoimmun Rev 19:102567. https://doi.org/10.1016/j.autrev.2020.102567CrossRef

107.

Gao Q, Bao L, Mao H et al (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369:77–81. https://doi.org/10.1126/science.abc1932CrossRef

108.

Mallapaty S (2021) China COVID vaccine reports mixed results—what does that mean for the pandemic. Nature. https://doi.org/10.1038/d41586-021-00094-zCrossRef

109.

Baden LR, El Sahly HM, Essink B et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384:403–416. https://doi.org/10.1056/NEJMoa2035389CrossRef

110.

Polack FP, Thomas SJ, Kitchin N et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577CrossRef

111.

Chen H, Mao Y, Duan Z et al (2021) Three cases of COVID-19 variant Delta with and without vaccination—Chengdu City, Sichuan Province. China CDC Wkly 3:544–546. https://doi.org/10.46234/ccdcw2021.137

112.

Krammer F (2020) SARS-CoV-2 vaccines in development. Nature 586:516–527. https://doi.org/10.1038/s41586-020-2798-3CrossRef

113.

Mishra SK, Tripathi T (2021) One year update on the COVID-19 pandemic: where are we now? Acta Trop 214:105778. https://doi.org/10.1016/j.actatropica.2020.105778CrossRef

114.

Fatima U, Rizvi SSA, Fatima S, Hassan MI (2020) Impact of hydroxychloroquine/chloroquine in COVID-19 therapy: two sides of the coin. J Interferon Cytokine Res 40:469–471. https://doi.org/10.1089/jir.2020.0105CrossRef

115.

Funnell SGP, Dowling WE, Muñoz-Fontela C et al (2020) Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients. Nat Commun 11:4253. https://doi.org/10.1038/s41467-020-17907-wCrossRef

116.

Singh B, Ryan H, Kredo T, Chaplin M, Fletcher T (2021) Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19. Cochrane Database Syst Rev 2:CD013587. https://doi.org/10.1002/14651858.CD013587.pub2

117.

Cao B, Wang Y, Wen D et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med 382:1787–1799. https://doi.org/10.1056/NEJMoa2001282CrossRef

118.

Fan Z, Chen L, Li J et al (2020) Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol 18:1561–1566. https://doi.org/10.1016/j.cgh.2020.04.002CrossRef

119.

Lim J, Jeon S, Shin HY et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35:e79. https://doi.org/10.3346/jkms.2020.35.e79CrossRef

120.

Beigel JH, Tomashek KM, Dodd LE et al (2020) Remdesivir for the treatment of COVID-19—final report. Report N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764CrossRef

121.

WHO Solidarity Trial Consortium, Pan H, Peto R et al (2021) Repurposed antiviral drugs for COVID-19—interim WHO solidarity trial results. N Engl J Med 384:497–511CrossRef

122.

Wang Y, Zhang D, Du G et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569–1578CrossRef

123.

Ghosn L, Chaimani A, Evrenoglou T et al (2021) Interleukin-6 blocking agents for treating COVID-19: a living systematic review. Cochrane Database Syst Rev 3:CD013881. https://doi.org/10.1002/14651858.CD013881

124.

Juul S, Nielsen EE, Feinberg J et al (2021) Interventions for treatment of COVID-19: 2nd edition of a living systematic review with meta-analyses and trial sequential analyses (the LIVING Project). PLoS One 16:e0248132. https://doi.org/10.1371/journal.pone.0248132

125.

Hu L, Chen S, Fu Y et al (2020) Risk factors associated with clinical outcomes in 323 coronavirus disease 2019 (COVID-19) hospitalized patients in Wuhan, China. Clin Infect Dis 71:2089–2098. https://doi.org/10.1093/cid/ciaa539CrossRef

126.

Shaker MS, Oppenheimer J, Grayson M et al (2020) COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract 8:1477–1488.e5. https://doi.org/10.1016/j.jaip.2020.03.012CrossRef

127.

Johnston SL (2020) Asthma and COVID-19: is asthma a risk factor for severe outcomes? Allergy 75:1543–1545. https://doi.org/10.1111/all.14348CrossRef

128.

Caminati M, Lombardi C, Micheletto C et al (2020) Asthmatic patients in COVID-19 outbreak: few cases despite many cases. J Allergy Clin Immunol 146:541–542. https://doi.org/10.1016/j.jaci.2020.05.049CrossRef

129.

Garg S, Kim L, Whitaker M et al (2020) Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, 1–30 Mar 2020. MMWR Morb Mortal Wkly Rep 69:458–464. https://doi.org/10.15585/mmwr.mm6915e3

130.

To T, Viegi G, Cruz A et al (2020) A global respiratory perspective on the COVID-19 pandemic: commentary and action proposals. Eur Respir J 56. https://doi.org/10.1183/13993003.01704-2020

131.

Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L (2020) Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol 146:327-329.e4. https://doi.org/10.1016/j.jaci.2020.06.001CrossRef

132.

Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E (2021) COVID-19 susceptibility in bronchial asthma. J Allergy Clin Immunol Pract 9:684-692.e1. https://doi.org/10.1016/j.jaip.2020.11.020CrossRef

133.

Caminati M, Vultaggio A, Matucci A et al (2021) Asthma in a large COVID-19 cohort: prevalence, features, and determinants of COVID-19 disease severity. Respir Med 176:106261. https://doi.org/10.1016/j.rmed.2020.106261CrossRef

134.

Mendes NF, Jara CP, Mansour E, Araújo EP, Velloso LA (2021) Asthma and COVID-19: a systematic review. Allergy Asthma Clin Immunol 17:5. https://doi.org/10.1186/s13223-020-00509-yCrossRef

135.

World Health Organization (WHO) (2020) Chronic respiratory diseases: asthma. https://www.who.int/news-room/q-a-detail/chronic-respiratory-diseases-asthma. Accessed 31^st Oct 2021

136.

Ritchie AI, Jackson DJ, Edwards MR, Johnston SL (2016) Airway epithelial orchestration of innate immune function in response to virus infection. A focus on asthma. Ann Am Thorac Soc 13 Suppl 1:S55-S63. https://doi.org/10.1513/AnnalsATS.201507-421MG

137.

Yang JM, Koh HY, Moon SY et al (2020) Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study. J Allergy Clin Immunol 146:790–798. https://doi.org/10.1016/j.jaci.2020.08.008CrossRef

138.

Radzikowska U, Ding M, Tan G et al (2020) Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy 75:2829–2845. https://doi.org/10.1111/all.14429CrossRef

139.

Sajuthi SP, DeFord P, Jackson ND et al (2020) Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. bioRxiv 034454. https://doi.org/10.1101/2020.04.09.034454

140.

Song J, Zeng M, Wang H et al (2021) Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19. Allergy 76:483–496. https://doi.org/10.1111/all.14517CrossRef

141.

Ziegler CGK, Allon SJ, Nyquist SK et al (2020) SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181:1016-1035.e19. https://doi.org/10.1016/j.cell.2020.04.035CrossRef

142.

Carli G, Cecchi L, Stebbing J, Parronchi P, Farsi A (2021) Is asthma protective against COVID-19? Allergy 76:866–868. https://doi.org/10.1111/all.14426CrossRef

143.

Halpin DMG, Singh D, Hadfield RM (2020) Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J 55. https://doi.org/10.1183/13993003.01009-2020

144.

Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A (2020) Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med 8:436–438. https://doi.org/10.1016/S2213-2600(20)30167-3CrossRef

145.

Peters MC, Sajuthi S, Deford P et al (2020) COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. Am J Respir Crit Care Med 202:83–90. https://doi.org/10.1164/rccm.202003-0821OCCrossRef

146.

Hoffmann M, Kleine-Weber H, Schroeder S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181:271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052CrossRef

147.

Gill MA, Liu AH, Calatroni A et al (2018) Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 141:1735-1743.e9. https://doi.org/10.1016/j.jaci.2017.07.035CrossRef

148.

Lommatzsch M, Stoll P, Virchow JC (2020) COVID-19 in a patient with severe asthma treated with omalizumab. Allergy 75:2705–2708. https://doi.org/10.1111/all.14456CrossRef

149.

Ludvigsson JF (2020) Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 109:1088–1095. https://doi.org/10.1111/apa.15270CrossRef

150.

Yonker LM, Neilan AM, Bartsch Y et al (2020) Pediatric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): clinical presentation, infectivity, and immune responses. J Pediatr 227:45-52.e5. https://doi.org/10.1016/j.jpeds.2020.08.037CrossRef

151.

Bunyavanich S, Do A, Vicencio A (2020) Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA 323:2427–2429. https://doi.org/10.1001/jama.2020.8707CrossRef

152.

Liu Y, Yan LM, Wan L et al (2020) Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 20:656–657. https://doi.org/10.1016/S1473-3099(20)30232-2CrossRef

153.

Yang J, Zheng Y, Gou X et al (2020) Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 94:91–95. https://doi.org/10.1016/j.ijid.2020.03.017CrossRef

154.

Götzinger F, Santiago-García B, Noguera-Julián A et al (2020) COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 4:653–661. https://doi.org/10.1016/S2352-4642(20)30177-2CrossRef

155.

DeBiasi RL, Song X, Delaney M et al (2020) Severe coronavirus disease-2019 in children and young adults in the Washington, DC, metropolitan region. J Pediatr 223:199-203.e1. https://doi.org/10.1016/j.jpeds.2020.05.007CrossRef

156.

Swann OV, Holden KA, Turtle L et al (2020) Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 370:m3249. https://doi.org/10.1136/bmj.m3249CrossRef

157.

Kara AA, Böncüoğlu E, Kıymet E et al (2021) Evaluation of predictors of severe-moderate COVID-19 infections at children: a review of 292 children. J Med Virol 93:6634–6640. https://doi.org/10.1002/jmv.27237CrossRef

158.

Ouldali N, Yang DD, Madhi F et al (2021) Factors associated with severe SARS-CoV-2 infection. Pediatrics 147. https://doi.org/10.1542/peds.2020-023432

159.

Antoon JW, Grijalva CG, Thurm C et al (2021) Factors associated with COVID-19 disease severity in US children and adolescents. J Hosp Med 16:603–610. https://doi.org/10.12788/jhm.3689

160.

Zheng F, Liao C, Fan QH et al (2020) Clinical characteristics of children with coronavirus disease 2019 in Hubei. China Curr Med Sci 40:275–280. https://doi.org/10.1007/s11596-020-2172-6CrossRef

161.

Tagarro A, Epalza C, Santos M et al (2020) Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid. JAMA Pediatr, Spain. https://doi.org/10.1001/jamapediatrics.2020.1346CrossRef

162.

González-García N, Castilla-Peón MF, Solórzano Santos F et al (2021) COVID-19 incidence and mortality by age strata and comorbidities in Mexico City: a focus in the pediatric population. Front Public Health 9:738423. https://doi.org/10.3389/fpubh.2021.738423

163.

Floyd GC, Dudley JW, Xiao R et al (2021) Prevalence of asthma in hospitalized and non-hospitalized children with COVID-19. J Allergy Clin Immunol Pract 9:2077-2079.e2. https://doi.org/10.1016/j.jaip.2021.02.038CrossRef

164.

Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D (2020) Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis 20:689–696. https://doi.org/10.1016/S1473-3099(20)30198-5CrossRef

165.

Sun D, Li H, Lu XX et al (2020) Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World J Pediatr 16:251–259. https://doi.org/10.1007/s12519-020-00354-4CrossRef

166.

Chao JY, Derespina KR, Herold BC et al (2020) Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a tertiary care medical center in New York City. J Pediatr 223:14-19.e2. https://doi.org/10.1016/j.jpeds.2020.05.006CrossRef

167.

Zhou MY, Xie XL, Peng YG et al (2020) From SARS to COVID-19: what we have learned about children infected with COVID-19. Int J Infect Dis 96:710–714. https://doi.org/10.1016/j.ijid.2020.04.090CrossRef

Titel: Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
verfasst von: Jin-jin Zhang
Xiang Dong
Guang-hui Liu
Ya-dong Gao
Publikationsdatum: 19.01.2022
Verlag: Springer US
Schlagwort: COVID-19
Erschienen in: Clinical Reviews in Allergy & Immunology / Ausgabe 1/2023
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-022-08921-5

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

Abstract

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis

Public Health Measures and the Control of COVID-19 in China

Clinical Application of Antibody Immunity Against SARS-CoV-2: Comprehensive Review on Immunoassay and Immunotherapy

Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement

Das persistierende Post-COVID-Syndrom: Ursachen und Behandlungsstrategien

Neu im Fachgebiet HNO

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

Klinikreform soll zehntausende Menschenleben retten

Eingreifen von Umstehenden rettet vor Erstickungstod

Update HNO